MARKET

HROW

HROW

Harrow Health Inc
NASDAQ
44.56
+0.17
+0.38%
After Hours: 44.65 +0.09 +0.20% 19:25 12/18 EST
OPEN
44.87
PREV CLOSE
44.39
HIGH
45.69
LOW
44.19
VOLUME
398.33K
TURNOVER
--
52 WEEK HIGH
51.30
52 WEEK LOW
20.85
MARKET CAP
1.65B
P/E (TTM)
-292.5804
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HROW last week (1208-1212)?
Weekly Report · 3d ago
Noteworthy Friday Option Activity: HROW, EWTX, RBLX
NASDAQ · 6d ago
Undercovered Dozen: USA Rare Earth, Santacruz Silver, Western Midstream, Visa And More
Seeking Alpha · 12/08 16:31
Weekly Report: what happened at HROW last week (1201-1205)?
Weekly Report · 12/08 10:02
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS
Seeking Alpha · 12/01 13:00
Weekly Report: what happened at HROW last week (1124-1128)?
Weekly Report · 12/01 09:58
A Retirement Portfolio That Beats The S&P 500
Seeking Alpha · 11/25 22:30
Weekly Report: what happened at HROW last week (1117-1121)?
Weekly Report · 11/24 10:02
More
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

Webull offers Harrow Inc stock information, including NASDAQ: HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.